The GLP is committed to full transparency. Download and review our 2019 Annual Report

‘It’s very encouraging’: Experimental gene therapy shows promise for glioblastoma patients in clinical trial

| | August 22, 2019

An inducible, tumor-localized gene therapy has been tested for the first time in glioblastoma patients. The two-part approach, which involves receiving an injection of an immune-activator gene into the brain tumor site and swallowing a pill that switches on the gene, resulted in the production of the activator—interleukin 12 (IL-12)—and an infiltration of immune cells into tumor tissue, according to a report in Science Translational Medicine [August 14]. The results also hint that patients’ survival may be prolonged by the treatment.

Patients in this group survived on average 12.7 months after surgery, with 26.7 percent and 13.3 percent surviving to 18 months and 24 months, respectively.

“We don’t get too excited about Phase 1 survival data,” says neurosurgeon Mitchel Berger of the University of California, San Francisco, who was not involved in the trial. Although, he adds, “when you consider the fact that recurrent glioblastoma is a deadly disease that usually has one or two percent of patients alive at two [years] . . . to have a median overall survival of twelve months and somewhere a little bit over ten percent of patients alive at twenty-four months is pretty darn good. It’s very encouraging.”

Read full, original post: Immune-Activating Gene Therapy for Glioblastoma

Related article:  Taking cancers apart ‘piece-by-piece’ in search for vulnerabilities that could be attacked with precision medicine
The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend